CA
TSHA icon

Cliff Asness’s Taysha Gene Therapies TSHA Stock Holding History

Cliff Asness’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$877K Sell
128,764
-48,545
-27% -$287K ﹤0.01% 3081
2026
Q1 		$793K Buy
177,309
+8,447
+5% +$39.3K ﹤0.01% 2896
2025
Q4 		$929K Buy
168,862
+17,862
+12% +$86.7K ﹤0.01% 2601
2025
Q3 		$494K Buy
151,000
+15,234
+11% +$43.1K ﹤0.01% 2819
2025
Q2 		$314K Buy
135,766
+27,867
+26% +$60.5K ﹤0.01% 2854
2025
Q1 		$150K Buy
107,899
+82,545
+326% +$138K ﹤0.01% 2942
2024
Q4 		$43.9K Sell
25,354
-44,117
-64% -$91.5K ﹤0.01% 2818
2024
Q3 		$140K Buy
+69,471
New +$152K ﹤0.01% 2622
2022
Q3 		– Sell
-10,134
Closed -$38K – 2323
2022
Q2 		$38K Buy
+10,134
New +$40.2K ﹤0.01% 2146

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cliff Asness's TSHA Position: Q2 2026 in Review

Cliff Asness reduced its Taysha Gene Therapies (TSHA) stake by 27% in Q2 2026, selling an estimated $287K and leaving 128,764 shares worth $877K. The position accounts for ﹤0.01% of the portfolio, ranked #3081.

Cliff Asness first reported a position in TSHA in Q2 2022 and has held it in 9 quarters since. The position peaked at $929K in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Cliff Asness held 128,764 shares of Taysha Gene Therapies worth $877K as of Q2 2026.
  • Cliff Asness sold 48,545 Taysha Gene Therapies shares in Q2 2026, an estimated $287K.
  • Taysha Gene Therapies made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3081 holding.
  • Cliff Asness first reported a position in Taysha Gene Therapies in Q2 2022 and has held it in 9 quarters since.
  • Cliff Asness's Taysha Gene Therapies position peaked at $929K in Q4 2025.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.